
From: William Daniels [/O=REGENERON/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=WILLIAM.DANIELS]
Sent: Friday, December 06, 2013 2:18:26 PM
To: Robert Davis
CC: Robert Krukowski; Cathy Casey
Subject: RE: report + additional questions
Importance: High

Bob,

I had already told him it was a verbal conversation so I have no email to document, I can reiterate that.

I'm comfortable with saying that she does provide a projection of the # of patients and they correlating dollars they would require to be supported for the year, which I validate based on E4U data, are you and Bob T good with that?

Regards,
Bil

From: Robert Davis
Sent: Friday, December 06, 2013 7:28 AM
To: William Daniels
Cc: Robert Krukowski; Cathy Casey
Subject: Re: report + additional questions

Wait to answer

Thank You,

Bob Davis
Executive Director & Head of
Trade, Reimbursement & Managed Markets
Office: 914-847-7690

Sent from my iPad

On Dec 6, 2013, at 7:26 AM, "John Calabro" <John.Calabro@regeneron.com> wrote:

Bill:

When she makes a request for additional funding, how does she justify it? Can you send me an example email?

Thanks,

John

From: William Daniels
Sent: Thursday, December 05, 2013 4:48 PM
To: John Calabro
Cc: Robert Davis; Robert Krukowski; Cathy Casey
Subject: Re: report + additional questions

John,

No I don't receive any other reports or data

My contact estimates what she needs for the year verbally and then we divide across the year when we can afford it. If she is running low, she calls and indicates what more she needs.

Bil Daniels
REGENERON Pharmaceuticals
Tel: 914.606.0878

Sent from my iPad

On Dec 5, 2013, at 3:24 PM, "John Calabro" <John.Calabro@regeneron.com> wrote:

Bill:

Can you please respond to the email below?

Thanks,

John

From: John Calabro
Sent: Wednesday, December 04, 2013 8:43 AM
To: William Daniels
Cc: Robert Davis; Robert Krukowski; Cathy Casey
Subject: re: report + additional questions
Importance: High

Hi Bill:

It turns out the report is attached, for some reason it doesn't show up on the i-phone.

I did forget to confirm a couple of things with you yesterday:

- Do you receive any other reports or data in emails from CDF? If so, please provide
- How does CDF make a request for additional funding? Is it verbal or by email? How do they justify it? Please provide any documentation you might have regarding such requests.

Thanks,

John

John P. Calabro, CPA, CIA
Executive Director, Internal Audit
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Rd.
Tarrytown, NY. 10591
914-847-7986